Related Experiment Videos
What the guidelines do not say: statin non-benefit groups
Pamela B Morris1, Kellie McLain
1Medical University of South Carolina, 25 Courtenay Drive, MSC 592, Charleston, SC, 29425, USA, morrispa@musc.edu.
Insights
The 2013 guidelines identify four statin benefit groups for atherosclerotic cardiovascular disease (ASCVD) risk reduction. Clinicians must consider evidence limitations for patients outside these groups to personalize statin therapy decisions.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Background:
- The 2013 ACC/AHA guidelines define four primary groups of adults (40-75 years) who benefit from statin therapy to reduce atherosclerotic cardiovascular disease (ASCVD) risk.
- These groups include individuals with clinical ASCVD, diabetes, LDL-C >190 mg/dl, or a 10-year ASCVD risk ≥7.5% via the Cardiovascular Risk Calculator.
Purpose of the Study:
- To address the challenge clinicians face with patients who do not clearly fit into the established statin-benefit groups.
- To guide personalized decision-making and inform patient discussions about statin therapy risks and benefits for those outside the primary benefit groups.
Main Methods:
- Review and synthesis of existing evidence and guidelines pertaining to statin therapy.
- Analysis of the limitations of current guidelines for specific patient populations.
- Emphasis on shared decision-making between clinicians and patients.
Main Results:
- The established guidelines provide clear recommendations for four specific statin-benefit groups.
- A significant number of patients do not neatly fall into these defined categories, requiring nuanced clinical judgment.
- Understanding guideline limitations is crucial for appropriate statin use in broader patient populations.
Conclusions:
- Personalized patient care requires considering factors beyond the four primary statin-benefit groups.
- Clinicians need to be aware of the evidence gaps and additional guidelines for statin non-benefit groups.
- Informed clinician-patient discussions are essential for optimizing statin therapy decisions and managing ASCVD risk.
Abstract:
The 2013 American College of Cardiology/American Heart Association guidelines for management of low-density lipoprotein cholesterol (LDL-C) to reduce atherosclerotic cardiovascular disease (ASCVD) risk identified four groups of adults (40-75 years of age) with significant evidence for benefit from statin therapy: presence of clinical ASCVD or diabetes, age ≥21 years and LDL-C >190 mg/dl, and 10-year risk of hard ASCVD events ≥7.5 % as determined by the new Cardiovascular Risk Calculator. However, clinicians are faced daily with at-risk patients who do not clearly match one of these statin-benefit groups. Understanding the limitations of available evidence and awareness of additional published guidelines for statin non-benefit groups will help practitioners make personalized decisions with patients and inform the clinician-patient discussion regarding potential risks and benefits of statin therapy.